Home / Technology & Devices (page 5)

Technology & Devices

Pacira to Acquire Medical Technology Company MyoScience for $220 Million

PARSIPPANY, N.J. and FREMONT, Calif., March 05, 2019 (GLOBE NEWSWIRE) — Pacira Pharmaceuticals, Inc. (“Pacira”) (NASDAQ: PCRX) and MyoScience, Inc. (“MyoScience”), a privately held medical technology company, today announced the signing of a definitive agreement for the acquisition of MyoScience by Pacira. MyoScience currently markets the ioveraº system, a novel, FDA-approved non-opioid treatment that alleviates pain through a mechanism …

Read More »

MaxCyte and Kite Enter Multi-Drug CAR-T Technology Deal

Gaithersburg, Maryland – 01 March 2019: MaxCyte (LSE: MXCT, MXCS), the global cell-based medicines and life sciences company, announced today that it has expanded its relationship with Kite, a Gilead Company, by entering into a multi-drug clinical and commercial agreement. Under the terms of the agreement, Kite will use MaxCyte’s Flow Electroporation® Technology to enable …

Read More »

FDA Grants Breakthrough Device Designation to T2 Biosystems’ T2Resistance Panel

LEXINGTON, Mass., Feb. 27, 2019 (GLOBE NEWSWIRE) — The FDA has granted T2 Biosystems, Inc. (NASDAQ:TTOO) “Breakthrough Device” designation for the T2Resistance Panel, a diagnostic panel that can detect 13 resistance genes from both gram-positive and gram-negative pathogens from a single patient blood sample, without the wait for blood culture. The 13 …

Read More »

Myriad’s BRACAnalysis CDx Test Successfully Identified Patients with Metastatic Pancreatic Cancer Who Benefited from Treatment with Olaparib

SALT LAKE CITY, Feb. 26, 2019 (GLOBE NEWSWIRE) — Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in personalized medicine, today announced that the Phase III POLO study demonstrated its BRACAnalysis CDx®  test successfully identified patients with metastatic pancreatic cancer who have BRCA mutations and benefitted from treatment with olaparib, a novel PARP inhibitor.  Myriad …

Read More »

Natera Announces Publication of Analytical Validation Study Demonstrating Superior Precision of Its Kidney Transplant Rejection Assay

SAN CARLOS, Calif., Feb. 22, 2019 /PRNewswire/ –Natera, Inc. (NASDAQ: NTRA), a leader in cell-free DNA, today announced analytical validation study results to be published online in the journal  Transplantation demonstrating the superior performance of its donor-derived cell-free DNA (dd-cfDNA) test for detecting active rejection in kidney transplant recipients.1 The study showed superior assay …

Read More »

Gamida Cell and Editas Medicine Partner to Evaluate Use of CRISPR Genome Editing Technology in NAM-NK Cells

BOSTON–(BUSINESS WIRE)–Gamida Cell Ltd. (Nasdaq: GMDA), a leading cellular and immune therapeutics company, today announced an agreement with Editas Medicine, Inc., a leading genome editing company, to evaluate the potential use of Editas Medicine’s CRISPR technology to edit NAM-NK cells, which are natural killer cells that have been expanded using Gamida …

Read More »

Medtronic Receives FDA Breakthrough Designation for Developing Personalized Closed Loop Insulin Pump System for Diabetes Management

DUBLIN – February 19, 2019 – Medtronic plc (NYSE:MDT), the global leader in medical technology, today announced it has received Breakthrough Device designation from the U.S. Food and Drug Administration (FDA) for its Personalized Closed Loop (PCL) insulin pump system, currently in development. The PCL technology is designed to automate insulin …

Read More »

Novartis Enters 10-Target Antibody Discovery Deal with AbCellera

VANCOUVER, British Columbia–(BUSINESS WIRE)–AbCellera, a technology leader in therapeutic antibody discovery from natural immune repertoires, today announced a multi-target and multi-year collaboration with Novartis. Under the agreement, AbCellera will apply its expertise in antibody discovery and its single-cell screening technology to advance programs on up to ten targets elected by …

Read More »

Amgen Enters Multi-Target Collaboration with Abilita Bio for its Membrane Protein Technology

SAN DIEGO, Feb. 13, 2019 /PRNewswire/ — Abilita Bio, Inc. announced today that it has entered into a multi-target research collaboration agreement with Amgen, a world leader in biotechnology. Under the terms of the agreement, Abilita Bio will leverage its proprietary Enabled Membrane Protein (EMP™) technology platform to support Amgen’s …

Read More »

Johnson & Johnson to Acquire Robotic Surgery Company Auris Health for $3.4 Billion

New Brunswick, NJ – February 13, 2019 – Focused on creating the next frontier of surgery, Johnson & Johnson (NYSE: JNJ), today announced that Ethicon, Inc., entered into a definitive agreement to acquire Auris Health, Inc. for approximately $3.4 billion in cash. Additional contingent payments of up to $2.35 billion, in the aggregate, …

Read More »